Prognostic Added Value of <scp>GFAP</scp> in Patients With Minor Ischemic Stroke

Andrea Morotti declared consulting fees from AstraZeneca and EMG-REG International. Henrik Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). Andrea Pilotto received consultancy/speaker fees from Abbvie, Angelini, Bial, Eli Lilly, Lundbeck, Roche and Zambon pharmaceuticals. He acts as a consultant as part of the advisory Board of Angelini Pharma and BIAL pharmaceutics. Alessandro Padovani received personal compensation as a consultant/scientific advisory board member for Biogen, Eisai Eli Lilly, General Healthcare (GE), Lundbeck, Nestlè, Roche. All the other authors have no disclosures to report. The data that support the findings of this study are available from the corresponding author upon reasonable request.